再鼎医药Zai Lab Limited（ZLAB）2020年年度报告「NASDAQ」（英文版）（275页）.pdf

1、2020 ANNUAL REPORT2020 ANNUAL REPORT(incorporated in the Cayman Islands with limited liability)HKEX:9688NASDAQ:ZLABZai Lab LimitedZai Lab LimitedCONTENTSCHAIRPERSONS STATEMENT IIDEFINITIONS VCORPORATE INFORMATION VIIFINANCIAL HIGHLIGHTS IXEXEMPTIONS AND WAIVERS XRESEARCH AND DEVELOPMENT ACTIVITIES X

2、IIINDEPENDENT AUDITORS REPORT XIIICONSOLIDATED FINANCIAL STATEMENTS XVIIIFORM 10-K LXVADDITIONAL INFORMATION LXVIIICHAIRPERSONS STATEMENTSamantha Du,PhDFounder,Chairpersonand Chief Executive OfficerMarch 1,2021Dear Zai Lab Shareholders,Im pleased to report to you that 2020 was another year of strong

3、 execution and growth at Zai Lab.We received new product approvals,executed successful commercial launches,submitted key regulatory filings,announced important data readouts,established transformative partnerships,expanded into new disease areas and reinforced existing disease strongholds,brought in

4、 significant capital through equity financings,and made important new hires throughout the organization.Im particularly proud of everything our team accomplished in 2020 given the challenges posed by the COVID-19 pandemic.We successfully launched ZEJULA,for both second-line and first-line ovarian ca

5、ncer,and Optune for both newly-diagnosed and recurrent glioblastoma in China.We submitted new drug applications,which were accepted with priority review,for QINLOCK for fourth-line gastrointestinal stromal tumors and for NUZYRA for community-acquired bacterial pneumonia and for acute bacterial skin

6、and skin structure infections in China.And we expanded our pipeline and strengthened several of our disease franchises by forging new strategic partnerships with four leading biopharmaceutical companies for five important compounds.Our portfolio now includes 21 innovative products,including 17 in cl